<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01978418</url>
  </required_header>
  <id_info>
    <org_study_id>SAISTY-1</org_study_id>
    <nct_id>NCT01978418</nct_id>
  </id_info>
  <brief_title>Inhaled Salbutamol in Elective Caesarean Section</brief_title>
  <acronym>SAISTY</acronym>
  <official_title>Inhaled Salbutamol in Elective Caesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sture Andersson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The lungs of the fetus are filled with fluid and it is essential that fetal lung fluid is
      cleared at birth. This process is mediated through the activation of airway epithelial sodium
      channels (ENaC). In animals, ENaC is considered crucial for postnatal pulmonary adaptation.
      In humans, postnatal ENaC expression is dependent on gestational age and its activity,
      measured as nasal potential difference, correlates with lung compliance. Therefore, in the
      human newborn infant ENaC may be important for physiologic postnatal adaptation. The activity
      of ENaC is increased by beta-agonists, such as salbutamol. We hypothesize that low pulmonary
      expression or activity of ENaC in the perinatal period causes delayed clearance of lung fluid
      and thereby contributes to the risk for development of transient tachypnea of the newborn
      (TTN) in term infants born by Caesarean section (CS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We hypothesize that low pulmonary expression or activity of ENaC in the perinatal period
      causes delayed clearance of lung fluid and thereby contributes to the risk for development of
      transient tachypnea of the newborn (TTN) in term infants born by Caesarean section (CS). The
      aim of this study is to evaluate whether the respiratory status, measured by a transthoracic
      ultrasound method and lung compliance, of newborns infants born by CS can be improved by
      inhaled salbutamol at 30-60 minutes of age. 62 infants will be included and randomized to
      receive salbutamol or placebo-inhalations in a double-blind manner.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate whether lung ultrasound at 30-60 minutes of birth is improved at 3-6 hours of birth</measure>
    <time_frame>6 hours</time_frame>
    <description>To evaluate whether the respiratory status measured by a transthoracic ultrasound method of newborn infants born by CS can be improved by inhaled salbutamol at 30-60 minutes of age.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate whether lung compliance measured at 3-6 hours is improved by inhaled salbutamol at 30-60 minutes of age</measure>
    <time_frame>6 hours</time_frame>
    <description>To evaluate whether lung compliance of newborn infants born by CS can be improved by inhaled salbutamol at 30-60 minutes of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in respiratory rate at 3-6 hours of age</measure>
    <time_frame>6 hours</time_frame>
    <description>To see whether respiratory rate is decreased in infants receiving salbutamol at 30-60 minutes of age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To see whether there is a correlation between airway ENaC expression measured at 30-60 minutes of age and consequent lung fluid content at 3-6 hours of age</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whether cord blood cortisol concentrations correlate with expression of ENaC and further, with decrease in lung fluid content at 3-6 hours of age</measure>
    <time_frame>6 hours of age</time_frame>
    <description>whether cord blood cortisol concentrations correlate with expression of ENaC and further, with decrease in lung fluid content at 3-6 hours of age</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Postnatal Pulmonary Adaptation</condition>
  <condition>Cesarean Section</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo is administered once, at 30-60 minutes of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Salbutamol 0,4 mg inhalation, given once at 30-60 minutes of age</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salbutamol</intervention_name>
    <description>Medication given once as a dose of 4 puffs at 30-60 minutes of age</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Inhaled Ventoline (Evohaler) 0,1 mg/dos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo given once as a dose of four puffs at 30-60 minutes of age</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo, manufactured by GSK Finland</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy singleton pregnancy

          -  Cesarean section at 37 + 0 to 41 + 6 gestational weeks

        Exclusion Criteria:

          -  clinically significant congenital malformations

          -  birth weight &lt; 2000 grams

          -  intubation

          -  200 bp for more than 5 min

          -  relevant medication of the mother, e.g. albetol, beta-agonists (e.g. salbutamol,
             salmeterol), corticosteroids

          -  the suspicion of/confirmed pneumothorax or infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Hour</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sture Andersson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cecilia Janér, MD</last_name>
    <phone>+35894711</phone>
    <email>cecilia.janer@helsinki.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Otto M Helve, MD, PhD</last_name>
    <phone>+358505824426</phone>
    <email>otto.helve@helsinki.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Women's Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecilia Janér, MD</last_name>
      <phone>+35894711</phone>
      <email>cecilia.janer@helsinki.fi</email>
    </contact>
    <contact_backup>
      <last_name>Otto M Helve, MD, PhD</last_name>
      <phone>+358505824426</phone>
      <email>otto.helve@helsinki.fi</email>
    </contact_backup>
    <investigator>
      <last_name>Cecilia Janér, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Otto M Helve, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sture Andersson, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2013</study_first_submitted>
  <study_first_submitted_qc>October 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2013</study_first_posted>
  <last_update_submitted>December 5, 2014</last_update_submitted>
  <last_update_submitted_qc>December 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Sture Andersson</investigator_full_name>
    <investigator_title>Professor in Neonatology</investigator_title>
  </responsible_party>
  <keyword>Lung fluid</keyword>
  <keyword>Postnatal adaptation</keyword>
  <keyword>Salbutamol</keyword>
  <keyword>Albuterol</keyword>
  <keyword>Epithelial Sodium Channel</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

